Bristol Gate Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$71M Sell
61,388
-957
-2% -$1.13M 5.23% 1
2026
Q2
$74.8M Sell
62,345
-13,267
-18% -$13.6M 5.21% 3
2026
Q1
$69.5M Sell
75,612
-4,966
-6% -$5.03M 4.48% 10
2025
Q4
$86.6M Sell
80,578
-13,262
-14% -$12.7M 5% 2
2025
Q3
$71.6M Sell
93,840
-3,023
-3% -$2.25M 4.23% 15
2025
Q2
$75.5M Sell
96,863
-21,412
-18% -$16.6M 4.29% 14
2025
Q1
$97.7M Buy
+118,275
New +$98.4M 4.77% 8

Other funds holding LLY

Bristol Gate Capital Partners's LLY Position: Q3 2026 in Review

Bristol Gate Capital Partners reduced its Eli Lilly (LLY) stake by 1.5% in Q3 2026, selling an estimated $1.13M and leaving 61,388 shares worth $71M. The position accounts for 5.23% of the portfolio, ranked #1.

Bristol Gate Capital Partners first reported a position in LLY in Q1 2025 and has held it in 7 quarters since. The position peaked at $97.7M in Q1 2025. 4,631 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Bristol Gate Capital Partners held 61,388 shares of Eli Lilly worth $71M as of Q3 2026.
  • Bristol Gate Capital Partners sold 957 Eli Lilly shares in Q3 2026, an estimated $1.13M.
  • Eli Lilly made up 5.23% of Bristol Gate Capital Partners's portfolio in Q3 2026, its #1 holding.
  • Bristol Gate Capital Partners first reported a position in Eli Lilly in Q1 2025 and has held it in 7 quarters since.
  • Bristol Gate Capital Partners's Eli Lilly position peaked at $97.7M in Q1 2025.
  • 4,631 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Bristol Gate Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.